Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Patricia A. McDonnell is active.

Publication


Featured researches published by Patricia A. McDonnell.


Journal of Medicinal Chemistry | 2013

Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y1 Antagonist

Jennifer X. Qiao; Tammy C. Wang; Rejean Ruel; Carl Thibeault; Alexandre L’Heureux; William A. Schumacher; Steven A. Spronk; Sheldon Hiebert; Gilles Bouthillier; John Lloyd; Zulan Pi; Dora M. Schnur; Lynn M. Abell; Ji Hua; Laura A. Price; Eddie C.-K. Liu; Qimin Wu; Thomas E. Steinbacher; Jeffrey S. Bostwick; Ming Chang; Joanna Zheng; Qi Gao; Baoqing Ma; Patricia A. McDonnell; Christine Huang; Robert Rehfuss; Ruth R. Wexler; Patrick Y. S. Lam

Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y1 antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y12 antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y1 antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 3l will also be presented. Compound 3l was our first P2Y1 antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.


Bioorganic & Medicinal Chemistry Letters | 2013

Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: Observation of extensive dynamics in an enzyme/inhibitor complex.

Soong-Hoon Kim; Keith L. Constantine; Gerald J. Duke; Valentina Goldfarb; John T. Hunt; Stephen R. Johnson; Kevin Kish; Herbert E. Klei; Patricia A. McDonnell; William J. Metzler; Luciano Mueller; Michael A. Poss; Craig R. Fairchild; Rajeev S. Bhide

The design, synthesis and characterization of a phosphonate inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) is described. Compound 3, where the substrate C-9 oxygen was replaced with a nonlabile CH2 group, inhibits HDHD4 with a binding affinity (IC50 11μM) in the range of the native substrate Neu5Ac-9-P (compound 1, Km 47μM). Combined SAR, modeling and NMR studies are consistent with the phosphonate group in inhibitor 3 forming a stable complex with native Mg(2+). In addition to this key interaction, the C-1 carboxylate of the sugar interacts with a cluster of basic residues, K141, R104 and R72. Comparative NMR studies of compounds 3 and 1 with Ca(2+) and Mg(2+) are indicative of a highly dynamic process in the active site for the HDHD4/Mg(2+)/3 complex. Possible explanations for this observation are discussed.


Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2011

Cloning, purification, crystallization and preliminary X-ray analysis of the catalytic domain of human receptor-like protein tyrosine phosphatase γ in three different crystal forms.

Kevin Kish; Patricia A. McDonnell; Valentina Goldfarb; Mian Gao; William J. Metzler; David R. Langley; James W. Bryson; Susan E. Kiefer; Brian Carpenter; Walter Kostich; Ryan Westphal; Steven Sheriff

Protein tyrosine phosphatase γ is a membrane-bound receptor and is designated RPTPγ. RPTPγ and two mutants, RPTPγ(V948I, S970T) and RPTPγ(C858S, S970T), were recombinantly expressed and purified for X-ray crystallographic studies. The purified enzymes were crystallized using the hanging-drop vapor-diffusion method. Crystallographic data were obtained from several different crystal forms in the absence and the presence of inhibitor. In this paper, a description is given of how three different crystal forms were obtained that were used with various ligands. An orthorhombic crystal form and a trigonal crystal form were obtained both with and without ligand, and a monoclinic crystal form was only obtained in the presence of a particularly elaborated inhibitor.


Bioorganic & Medicinal Chemistry Letters | 2006

Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors

Kyoung S. Kim; Songfeng Lu; Lyndon A. M. Cornelius; Louis J. Lombardo; Robert M. Borzilleri; Gretchen M. Schroeder; Christopher X. Sheng; George C. Rovnyak; Donald Crews; Robert J. Schmidt; David K. Williams; Rajeev S. Bhide; Sarah C. Traeger; Patricia A. McDonnell; Luciano Mueller; Steven Sheriff; John A. Newitt; Andrew T. Pudzianowski; Zheng Yang; Robert Wild; Frances Y. Lee; Roberta Batorsky; James S. Ryder; Marie Ortega-Nanos; Henry Shen; Marco M. Gottardis; Deborah L. Roussell


Bioorganic & Medicinal Chemistry Letters | 2006

Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series

Christine M. Tarby; Robert F. Kaltenbach; Tram Huynh; Andrew T. Pudzianowski; Henry Shen; Marie Ortega-Nanos; Steven Sheriff; John A. Newitt; Patricia A. McDonnell; Neil T. Burford; Craig R. Fairchild; Wayne Vaccaro; Zhong Chen; Robert M. Borzilleri; Joseph G. Naglich; Louis J. Lombardo; Marco M. Gottardis; George L. Trainor; Deborah L. Roussell


Bioorganic & Medicinal Chemistry Letters | 2005

Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13)

Soong-Hoon Kim; Andrew T. Pudzianowski; Kenneth J. Leavitt; Joseph Barbosa; Patricia A. McDonnell; William J. Metzler; Bruce M. Rankin; Richard Liu; Wayne Vaccaro; William J. Pitts


Journal of Medicinal Chemistry | 2011

Small molecule receptor protein tyrosine phosphatase γ (RPTPγ) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop.

Steven Sheriff; B.R Beno; W Zhai; Walter Kostich; Patricia A. McDonnell; Kevin Kish; Goldfarb; M Gao; S.E Kiefer; J Yanchunas; Y Huang; S Shi; S Zhu; C Dzierba; J Bronson; John E. Macor; K.K Appiah; Ryan Westphal; J O'Connell; Samuel W. Gerritz


Analytical Biochemistry | 2009

Assessing compound binding to the Eg5 motor domain using a thermal shift assay

Patricia A. McDonnell; Joseph Yanchunas; John A. Newitt; Li Tao; Susan E. Kiefer; Marie Ortega; S. A. Kut; Neil T. Burford; Valentina Goldfarb; Gerald J. Duke; Henry Shen; William J. Metzler; Michael L. Doyle; Zhong Chen; Christine M. Tarby; Robert M. Borzilleri; Wayne Vaccaro; Marco M. Gottardis; Songfeng Lu; Donald Crews; Kyoung S. Kim; Louis J. Lombardo; Deborah L. Roussell


Journal of Medicinal Chemistry | 2008

Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.

Keith L. Constantine; Luciano Mueller; William J. Metzler; Patricia A. McDonnell; Gordon Todderud; Valentina Goldfarb; Yi Fan; John A. Newitt; Susan E. Kiefer; Mian Gao; David R. Tortolani; Wayne Vaccaro; John S. Tokarski


Journal of Molecular Recognition | 2006

NEMO binding domain of IKK-2 encompasses amino acids 735–745

Joann Strnad; Patricia A. McDonnell; Douglas James Riexinger; Claudio Mapelli; Lihong Cheng; Hilary Gray; Rolf Ryseck; James R. Burke

Collaboration


Dive into the Patricia A. McDonnell's collaboration.

Top Co-Authors

Avatar

William J. Metzler

University of Colorado Boulder

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John A. Newitt

Johns Hopkins University

View shared research outputs
Researchain Logo
Decentralizing Knowledge